Avutometinib + Defactinib
KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Key Facts
About Verastem Oncology
Verastem Oncology is on a mission to ensure no cancer patient runs out of treatment options by developing novel therapies for RAS/MAPK pathway-driven cancers, which are implicated in nearly a third of all cancers. The company achieved a significant milestone with the FDA approval of its combination therapy for KRAS-mutant recurrent low-grade serous ovarian cancer. Its clinical strategy is powered by a robust portfolio of ongoing trials and strategic collaborations, focusing on avutometinib as a backbone therapy in combination with agents like the FAK inhibitor defactinib to block compensatory pathways and drive deeper, more durable responses.
View full company profileAbout Verastem Oncology
Verastem Oncology is on a mission to ensure no cancer patient runs out of treatment options by developing novel therapies for RAS/MAPK pathway-driven cancers, which are implicated in nearly a third of all cancers. The company achieved a significant milestone with the FDA approval of its combination therapy for KRAS-mutant recurrent low-grade serous ovarian cancer. Its clinical strategy is powered by a robust portfolio of ongoing trials and strategic collaborations, focusing on avutometinib as a backbone therapy in combination with agents like the FAK inhibitor defactinib to block compensatory pathways and drive deeper, more durable responses.
View full company profileAbout Verastem Oncology
Verastem Oncology is on a mission to ensure no cancer patient runs out of treatment options by developing novel therapies for RAS/MAPK pathway-driven cancers, which are implicated in nearly a third of all cancers. The company achieved a significant milestone with the FDA approval of its combination therapy for KRAS-mutant recurrent low-grade serous ovarian cancer. Its clinical strategy is powered by a robust portfolio of ongoing trials and strategic collaborations, focusing on avutometinib as a backbone therapy in combination with agents like the FAK inhibitor defactinib to block compensatory pathways and drive deeper, more durable responses.
View full company profileAbout Verastem Oncology
Verastem Oncology is on a mission to ensure no cancer patient runs out of treatment options by developing novel therapies for RAS/MAPK pathway-driven cancers, which are implicated in nearly a third of all cancers. The company achieved a significant milestone with the FDA approval of its combination therapy for KRAS-mutant recurrent low-grade serous ovarian cancer. Its clinical strategy is powered by a robust portfolio of ongoing trials and strategic collaborations, focusing on avutometinib as a backbone therapy in combination with agents like the FAK inhibitor defactinib to block compensatory pathways and drive deeper, more durable responses.
View full company profile